Illumina, Inc. (NASDAQ:ILMN) Shares Bought by Strs Ohio

Strs Ohio increased its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 256.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 132,313 shares of the life sciences company’s stock after buying an additional 95,208 shares during the period. Strs Ohio owned about 0.09% of Illumina worth $22,958,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. First Citizens Bank & Trust Co. raised its position in shares of Illumina by 0.4% in the second quarter. First Citizens Bank & Trust Co. now owns 3,088 shares of the life sciences company’s stock worth $536,000 after buying an additional 12 shares during the last quarter. Patten Group Inc. raised its position in shares of Illumina by 2.7% in the first quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock worth $166,000 after buying an additional 25 shares during the last quarter. Puzo Michael J raised its position in shares of Illumina by 0.4% in the second quarter. Puzo Michael J now owns 5,955 shares of the life sciences company’s stock worth $1,032,000 after buying an additional 25 shares during the last quarter. Forte Capital LLC ADV raised its position in shares of Illumina by 1.6% in the first quarter. Forte Capital LLC ADV now owns 2,185 shares of the life sciences company’s stock worth $373,000 after buying an additional 35 shares during the last quarter. Finally, Gemmer Asset Management LLC raised its position in shares of Illumina by 5.7% in the first quarter. Gemmer Asset Management LLC now owns 686 shares of the life sciences company’s stock worth $117,000 after buying an additional 37 shares during the last quarter. 93.81% of the stock is currently owned by hedge funds and other institutional investors.

Illumina, Inc. (NASDAQ ILMN) traded down 0.21% during trading on Friday, reaching $194.25. 695,985 shares of the company’s stock were exchanged. The firm’s 50-day moving average price is $179.63 and its 200-day moving average price is $173.73. The firm has a market cap of $28.36 billion, a price-to-earnings ratio of 38.97 and a beta of 0.83. Illumina, Inc. has a 12 month low of $119.37 and a 12 month high of $199.95.

Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.68 by $0.14. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The firm had revenue of $662 million for the quarter, compared to analysts’ expectations of $642.38 million. During the same period in the previous year, the firm earned $0.86 earnings per share. The business’s revenue was up 10.3% compared to the same quarter last year. On average, equities research analysts anticipate that Illumina, Inc. will post $3.65 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This article was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://stocknewstimes.com/2017/08/12/illumina-inc-nasdaqilmn-position-increased-by-strs-ohio-updated.html.

A number of research firms have recently issued reports on ILMN. Zacks Investment Research downgraded shares of Illumina from a “buy” rating to a “hold” rating in a report on Friday, August 4th. Vetr upgraded shares of Illumina from a “buy” rating to a “strong-buy” rating and set a $197.84 price objective on the stock in a report on Tuesday, May 23rd. Morgan Stanley reiterated an “underweight” rating and issued a $115.00 price objective (up from $108.00) on shares of Illumina in a report on Monday, May 15th. First Analysis upgraded shares of Illumina from an “underweight” rating to an “equal weight” rating and set a $176.00 price objective on the stock in a report on Wednesday, August 2nd. Finally, Barclays PLC reiterated an “equal weight” rating and issued a $150.00 price objective on shares of Illumina in a report on Wednesday. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $177.01.

In related news, Director Frances Arnold sold 825 shares of Illumina stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $174.77, for a total transaction of $144,185.25. Following the sale, the director now directly owns 8,816 shares in the company, valued at $1,540,772.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Charles Dadswell sold 1,609 shares of Illumina stock in a transaction that occurred on Thursday, August 3rd. The shares were sold at an average price of $197.00, for a total value of $316,973.00. Following the sale, the senior vice president now owns 9,037 shares in the company, valued at $1,780,289. The disclosure for this sale can be found here. Insiders have sold 134,010 shares of company stock worth $23,946,015 over the last three months. Insiders own 1.60% of the company’s stock.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply